News Search Results
Jun 22, 2026, 11:44 ET Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
range of $76 million to $80 million. The Company attributed the revised outlook, in part, to market uncertainties affecting pharmaceutical and biotechnology customers, including budget reductions, project cancellations, and delays.Following this announcement, Simulations Plus stock declined more
More news about: Johnson Fistel, PLLP
Jun 22, 2026, 11:12 ET Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology
LYON and CAEN, France, June 22, 2026 /PRNewswire/ -- Lys Therapeutics, a French biotechnology company pioneering a novel approach targeting the tPA-NMDAr axis in neurodegenerative and neurovascular diseases, today announced that it has raised
More news about: Lys Therapeutics
Jun 22, 2026, 11:00 ET Lilly declares third-quarter 2026 dividend
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 22, 2026, 10:30 ET Fill Finish Manufacturing Market worth $30.37 billion by 2031 | MarketsandMarkets™
fill-finish manufacturing market during the forecast period. Growth is driven by increasing outsourcing of fill finish operations by pharmaceutical and biotechnology companies seeking to reduce costs, access specialized expertise, and accelerate time-to-market. Expanding biologics, biosimilars, and advanced therapy
More news about: MarketsandMarkets
Jun 22, 2026, 10:06 ET Integral Molecular Earns Back-to-Back Top Workplace Honors from The Philadelphia Inquirer
PHILADELPHIA, June 22, 2026 /PRNewswire/ -- Integral Molecular, a founding member of Philadelphia's biotechnology community, has again been named a Top Workplace by The Philadelphia Inquirer. The honor is based entirely on confidential employee feedback and
More news about: Integral Molecular
Jun 22, 2026, 09:00 ET Leerink Partners Expands Oncology Research Team with Addition of Asthika Goonewardene
he was a Senior Biotechnology Analyst at Bloomberg Intelligence, leading coverage of the global biotechnology sector. Earlier in his career, he held research and consulting roles focused on biotechnology and pharmaceutical innovation."Asthika is a highly respected biotechnology analyst with a strong
More news about: Leerink Partners
Jun 22, 2026, 09:00 ET EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that EverythingALS will host a conversation
More news about: NeuroSense
Jun 22, 2026, 09:00 ET Knoa Pharma to Present Pipeline Assets at BIO International Convention 2026
The Company will showcase its pipeline and invite conversations with potential partners at the biotechnology industry's premier global event, June 22–25.STAMFORD, Conn., June 22, 2026 /PRNewswire/
More news about: Knoa Pharma
Jun 22, 2026, 08:17 ET Rocket One Launches Swarm Stage AI™ to Counter Autonomous Drone Swarms
defense and space systems. The Company is also positioned to pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly
More news about: Rocket One Inc.
Jun 22, 2026, 08:02 ET Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections
Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin®
More news about: Lakewood-Amedex Biotherapeutics Inc.
Jun 22, 2026, 08:01 ET Raymond Rodriguez-Torres Appointed First Ascent Biomedical New President to Scale Functional Precision Oncology
Precision Oncology (FPO) and transform cancer treatment through biology-driven, patient-specific decision support. Bringing more than two decades of biotechnology and pharmaceuticals leadership experience, Rodriguez-Torres joins First Ascent at a time when physicians are increasingly seeking better tools to
More news about: First Ascent Biomedical
Jun 22, 2026, 08:00 ET Brenig Therapeutics to Present AI-Enabled Design of a Brain-Penetrant NLRP3 Inhibitor at Keystone Symposia Neuroinflammation in Health and Disease
BOSTON and SAN DIEGO, June 22, 2026 /PRNewswire/ -- Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company developing differentiated therapies for neurodegenerative and neuroinflammatory diseases, today announced that Alexei Pushechnikov, PhD,
More news about: Brenig Therapeutics Inc
Jun 22, 2026, 08:00 ET DropGenie Raises Seed+ Financing to Accelerate Commercialization of Its First Product
DropGenie, a biotechnology company advancing next-generation gene editing workflows, today announced the closing of its Seed+ financing to support the launch of its first
More news about: DropGenie
Jun 22, 2026, 07:30 ET REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
to, and 100 percent of any proceeds related to the potential sale of, the PRV.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jun 22, 2026, 07:05 ET AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
YouTube.About Apogee TherapeuticsApogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment
More news about: AbbVie
Jun 22, 2026, 07:00 ET Taiwan Biotech Delegation Heads to BIO 2026 to Advance Global Partnerships and Innovation
technologies from 33 companies at the world's largest biotechnology conventionSAN DIEGO, June 22, 2026 /PRNewswire/ -- Taiwan is showcasing the strength of its biotechnology ecosystem at BIO International Convention 2026 in
More news about: BPIPO
Jun 22, 2026, 07:00 ET Biond Biologics Appoints Giovanni Selvaggi, M.D., as Chief Medical Officer ("CMO")
physician-scientist and oncology drug development executive with extensive experience spanning academic medicine, global pharmaceutical companies, and biotechnology organizations. Over the course of his career, he has led the clinical development of multiple oncology programs from early-stage research through
More news about: Biond Biologics Ltd.
Jun 22, 2026, 07:00 ET AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
YouTube.About Apogee TherapeuticsApogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment
More news about: AbbVie
Jun 22, 2026, 05:15 ET ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing
worldwide.SINGAPORE, June 22, 2026 /PRNewswire/ -- ChemT Biotechnology, an AI-driven biotechnology company building the intelligence layer for biomanufacturing, has closed a US$4 million seed round led by Wavemaker Ventures, the
More news about: ChemT Biotechnology
Jun 22, 2026, 05:14 ET ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics
indications.Driving Preclinical Efficacy with Polku Therapeutics In further validation of the platform's utility, Polku Therapeutics, a biotechnology company developing disease-modifying therapies for neurodegenerative disorders, reported positive efficacy results for its lead compound, POLK-38.
More news about: ChemDiv, Inc
Jun 22, 2026, 04:04 ET H3 Zoom Closes Oversubscribed USD$3.6 Million Series A Round to Scale AI-Powered Inspection Intelligence Across Asia
conviction in transformative technologies across AI/ML, advanced materials, cybersecurity, space and communications, robotics, energy, health and biotechnology.For more information, visit:
More news about: H3 Zoom
Jun 22, 2026, 00:37 ET Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
breakthrough therapies, spanning both traditional small molecules and advanced new modalities, to address critical patient needs."As an AI-native biotechnology company, Insilico is redefining the efficiency of preclinical drug development through its advanced AI and automation platform, setting a new standard
More news about: Insilico Medicine
Jun 21, 2026, 20:30 ET Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
engine built for global impact, with search and development capabilities unconstrained by modality or geography. MPM BioImpact is a world-leading biotechnology investment firm, with over 30 years' experience creating and investing in innovative companies."We are very pleased to expand our partnerships
More news about: Antengene Corporation Limited
Jun 19, 2026, 11:00 ET Seoul National University Hospital to Expand Global K-Bio Collaboration at BIO USA 2026
SNUH will operate a standalone booth under the hospital's name at BIO USA.Organized by the Biotechnology Innovation Organization (BIO), BIO USA is widely recognized as the world's largest biotechnology industry event. It serves as a leading global platform where pharmaceutical companies, biotech
More news about: Seoul National University Hospital (SNUH)
Jun 19, 2026, 09:28 ET /C O R R E C T I O N -- Acurion/
development initiatives across the biotechnology ecosystem, including roles at Syner-G Biopharma, Sequoia Biotech, and Biocom.Rick Schmitt joins as VP of Technology Operations. He brings decades of technology leadership experience spanning healthcare, biotechnology, and enterprise systems, including
More news about: Acurion